Understanding Cialis: The Lilly Brand Medication
Lilly reached the settlement with generic drugmakers over a dispute on a unit dose patent set to expire in 2020. After its initial approval in 2003, Cialis’ exclusivity had been expected to end in November, just a month before Pfizer’s rival med Viagra.
What Are the Current Market Dynamics for Tadalafil?
Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (Tadalafil) and Alita (Pemetrexed), from Eli Lilly for selected ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand. The acquisition will take place via its wholly owned subsidiary, Zanovex Pte. Following the acquisition, it is intended that Zanovex will own the trademarks, marketing authorisations and licence manufacturing information for both Alimta, a chemotherapy drug for the treatment of certain types of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis, a men’s health product for the treatment of erectile dysfunction. The press release explains that: ‘ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a cialis comparison price broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand’.
Post-Patent Expiry Impact
John Graham, group CEO at Zuellig Pharma, commented: “This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia.” AACHEN, Germany, June 2, 2025 /PRNewswire/ -- Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men[1]. Grünenthal is a global leader in pain management and related diseases.
Regulatory Approvals
E-Mail: [email protected]Phone: +44 7917 196855 [1] In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. Leverage our omni-channel approach to grow your brand across Asia Pacific. The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region. As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. With the new agreement, Lilly can work to squeeze more branded sales out of a med that’s been an important contributor over the years.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 5mg | 120 + 6 Pills | 132.92€ 126.59€ | |
| Cialis Black | 80mg | 10 Pills | 43.27€ 41.21€ | |
| Cialis Super Active | 20mg | 60 + 8 Pills | 230.32€ 219.35€ | |
| Cialis Generic | 5mg | 60 + 4 Pills | 86.02€ 81.92€ | |
| Cialis Professional | 20mg | 90 + 2 Pills | 241.49€ 229.99€ | |
| Cialis Generic | 60mg | 10 Pills | 41.22€ 39.26€ | |
| Cialis Generic | 20mg | 90 + 6 Pills | 154.71€ 147.34€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Cialis Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Cialis Black | 80mg | 360 + 20 Pills | 639.78€ 609.31€ | |
| Cialis Generic | 20mg | 20 Pills | 54.72€ 52.11€ | |
| Cialis Generic | 40mg | 60 + 6 Pills | 130.98€ 124.74€ | |
| Cialis Generic | 20mg | 60 + 6 Pills | 117.76€ 112.15€ | |
| Cialis Generic | 5mg | 10 Pills | 29.39€ 27.99€ | |
| Cialis Generic | 2.5mg | 180 + 10 Pills | 154.86€ 147.49€ |
Last year, the drug turned in $1.469 billion in U.S.
- It is one of the "big three" PDE5 inhibitors alongside Viagra and Levitra.
- Its long duration is its primary competitive advantage.
- Daily dosing offers a unique positioning versus on-demand competitors.
- For BPH, it competes with alpha-blockers and 5-alpha reductase inhibitors.
- In the post-patent market, generic tadalafil is the main competitor.
- Brand strategy shifted to focus on specific patient segments.
- Combination therapies for BPH/ED are an area of clinical interest.
- Newer ED treatments (e.g., shockwave therapy) represent non-drug competition.
sales, or 7% of the drugmaker’s global haul.
Shipping Information
Comparatively speaking to other erectile dysfunction drugs, Cialis has a longer half-life of roughly around 17.5 hours. The benefits of Cialis on erectile function might last for up to 36 hours after taking the medication, even though the amount of the drug in your blood gradually declines. Although the FDA has not approved Cialis for usage in women, it is purposely intended to be only used by men for erectile dysfunction. Cialis's safety and effectiveness in women, however, are still up for debate, and the drug's use in this demographic has not been well tested. Cialis side effects for women can include headache, flushing, nausea, dizziness, and muscle soreness, much like for men.
Are they approved by the FDA (Food and Drug Administration)?
HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your healthcare professional for complete information about this product and your specific health needs. I've been using offshore cheap meds for 10 years.
Highest Development Phases
I have been purchasing my ED meds from offshore for 3 years. I will continue to buy from them as long as there is no problem with US customs. They have the best price around for this medication. Good site to use for affordable medicine. The site is easy to use and they remind me when it's time to refill my Prescription. RELATED: Top 10 U.S.
Summary of Market and Financial Outlook
In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow. A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD A. MENARINI ASIA-PACIFIC PRIVATE LIMITED A. MENARINI SINGAPORE PTE LTD A.
Uses and Benefits of Cialis:
MENARINI BIOMARKERS SINGAPORE PTE LTD Acquisition of Cialis® in the People’s Republic of China to bolster Menarini’s Men’s Health portfolio and drive multichannel coverage This is a significant milestone for Menarini Asia operations as it commemorates its 10th anniversary of being established in 13 major healthcare markets in Asia-Pacific 22/07/21, Singapore – A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world’s largest Italian biopharmaceutical company, announced today the completion of its acquisition of Cialis® in the People’s Republic of China from Eli Lilly and Company. Through the acquisition, Menarini will take over ownership of the brand and assume all sales, marketing and distribution responsibilities. Cialis® was first approved by the European Medicines Agency in 2002 followed by the U.S.
Revenue Projections for 2023-2025
Food and Drug Administration (“FDA”) in 2003 and then NMPA (National Medical Products Administration) in 2005, as well as in more than 120 other countries. With Cialis®, Menarini intends to strategically expand its nationwide coverage across the Retail, E-Commerce and Hospital channels and deliver on its growth ambition in the second-largest healthcare market worldwide. Besides Men’s Health, Menarini is focused on major therapeutic categories including Dermatology, Allergy/Respiratory, Cardiovascular, Gastroenterology, Pain Management, Consumer Healthcare, Oncology and Anti-Infectives. Maurizio Luongo, Chief Executive Officer, Menarini Asia-Pacific said, “The acquisition of Cialis® is a testament to Menarini’s commitment to invest and grow our well diversified Primary and Speciality Care portfolio in the Asia-Pacific region, which is an increasingly important engine of growth for the Group. We are excited to take the brand from strength to strength in China with our well proven, multi-pronged go-to-market strategy for our Men’s Health portfolio in China. patent losses of 2017 - Cialis In a statement, Lilly’s general counsel Michael Harrington said the “unit dose patent for Cialis is valid and infringed by companies seeking to market a generic version of Cialis.” He added the deal includes a “royalty-bearing license agreement that provides us with more certainty regarding our U.S.
- Cialis Lilly’s tadalafil is distinct for its longer half-life compared to sildenafil (Viagra).
- Patients report improvements in sexual performance and confidence.
- It also helps relieve symptoms of enlarged prostate, such as frequent urination.
- Cialis Lilly requires a prescription from a healthcare professional.
- Possible side effects include headache, indigestion, back pain, and muscle aches.
- It should not be combined with nitrates due to risk of severe hypotension.
- Cialis Lilly does not protect against sexually transmitted infections.
- The medication may interact with alpha-blockers, requiring caution.
- It should be stored at room temperature away from moisture and heat.
- Cialis Lilly is not recommended for use by women or children.
exclusivity.” Generics from Aurobindo, Teva Pharmaceutical, Alembic, Watson, Sun Pharma and Synthon are tentatively FDA-approved and ready to roll, according to Drugs@FDA.
- Cialis Lilly formulations comply with international pharmacopeial standards.
- The company has taken steps to reduce environmental impact in manufacturing Cialis.
- Lilly’s Cialis brand supports scientific publications and training for clinicians.
- Proper disposal of unused tablets is recommended to avoid unintended exposure.
- Cialis Lilly aids in improving overall male reproductive health and wellbeing.
- The brand logo and packaging ensure authenticity against counterfeit products.
- Partnerships with healthcare providers facilitate access to Cialis Lilly globally.
- The product is subject to continuous post-marketing surveillance for efficacy and safety.
- Specialty pharmacies provide additional patient education and monitoring.
- Cialis Lilly remains a cornerstone treatment in men’s sexual health management.
RELATED: Are Viagra and Cialis leaving TV advertising?
Adverse effects
For the Financial Year 2020, the Menarini Group clocked sales revenues of US 4.6 billion dollars, of which the Asia Pacific region has grown to become a dynamic engine of growth for the Group with more than 10% revenue contribution. For more information about Menarini Asia-Pacific, please visit: If you'd like to know more about Menarini, feel free to download our PDF files here. Under a new patent settlement with multiple generics makers, Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer. Cialis has generated more than $17 billion in sales during its patent life, which now extends at least through Sept. 27, 2018. Report forecasts end of ED era on NFL football 2 in FiercePharma’s report in May detailing the top patent losses of 2017.
| Parameter | Details | Notes |
|---|---|---|
| Absorption | Rapid, within 30-60 minutes | Food may delay absorption |
| Duration of Action | Up to 36 hours | Variable depending on individual |
| Metabolism | Primarily via CYP3A4 enzyme | Liver metabolism |
| Elimination Half-life | Approximately 17.5 hours | Long half-life allows flexible dosing |
At the time, analysts with life science commercial intelligence firm EvaluatePharma predicted the med would lose 96% of its sales by 2022, tumbling to $55 million that year as a host of cheap generics flood the market. Over the years, Lilly has grown its key ED brand with a great deal of advertising, building an identity around couples in bathtubs in TV ads and elsewhere.
How Might Market Dynamics Evolve?
We look forward to harnessing the combined strengths of the complementary products in this portfolio to invigorate lives and relationships across the nation.” Cialis is indicated in China for the treatment of men with erectile dysfunction (ED), and men with both ED and the signs and symptoms of benign prostatic hyperplasia. It is important to note that Cialis is not to be taken with medicines called "nitrates" such as nitroglycerin, as tadalafil may potentiate the hypotensive effect of nitrates; and also GC stimulator, such as riociguat. Menarini Asia-Pacific is a member order cialis professional without prescription of the Menarini Group, with a heritage of over 130 years and over 17,000 employees in more than 140 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men’s Health. But as it nears the end of its patent life, Lilly will likely pull back on advertising.